SUTRO BIOPHARMA, INC.

STRO · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
140
SEC Filings

Business Summary

Overview We are a clinical stage oncology company developing site-specific and novel-format antibody drug conjugates, or ADCs, enabled by our proprietary integrated cell-free protein synthesis platform, XpressCF , and our site-specific conjugation platform, XpressCF+ . We aim to design and develop therapeutics using the most relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, or iADCs, and dual-payload ADCs, or dpADCs. Our molecules are directed primarily aga...

Next Earnings

Q2 FY2026 — expected 2026-09-14

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionSTROdiscussed_in_filing Cybersecurity
topic_mentionSTROdiscussed_in_filing Cybersecurity
topic_mentionSTROdiscussed_in_filing Healthcare & Bio
topic_mentionSTROdiscussed_in_filing Platform & Ecosystem
topic_mentionSTROdiscussed_in_filing Healthcare & Bio
topic_mentionSTROdiscussed_in_filing Platform & Ecosystem

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-232025-12-310001193125-26-119873EDGAR106K words
2025-03-132024-12-310000950170-25-038884EDGAR—
2024-03-252023-12-310000950170-24-035949EDGAR—
2023-03-302022-12-310000950170-23-010976EDGAR—
2022-02-282021-12-310000950170-22-002312EDGAR—
2021-03-182020-12-310001564590-21-013945EDGAR—
2020-03-162019-12-310001564590-20-010890EDGAR—
2019-04-012018-12-310001564590-19-010253EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001193125-25-270036EDGAR71K words
2025-08-072025-06-300000950170-25-105219EDGAR—
2025-05-082025-03-310000950170-25-067072EDGAR—
2024-11-132024-09-300000950170-24-126407EDGAR—
2024-08-132024-06-300000950170-24-096336EDGAR—
2024-05-132024-03-310000950170-24-058718EDGAR—
2023-11-132023-09-300000950170-23-063037EDGAR—
2023-08-102023-06-300000950170-23-041416EDGAR—
2023-05-152023-03-310000950170-23-021976EDGAR—
2022-11-082022-09-300000950170-22-023279EDGAR—
2022-08-082022-06-300000950170-22-015584EDGAR—
2022-05-092022-03-310000950170-22-008531EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-230001193125-26-119844EDGAR3K words
2026-02-100001193125-26-044934EDGAR—
2025-12-170001193125-25-322859EDGAR—
2025-12-030001193125-25-306786EDGAR—
2025-11-060001193125-25-269833EDGAR—
2025-09-290001193125-25-223434EDGAR—
2025-08-070000950170-25-105159EDGAR—
2025-06-250000950170-25-089978EDGAR—
2025-06-100001193125-25-138481EDGAR—
2025-06-020001193125-25-133268EDGAR—

140 total filings indexed. 110 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001382101
TickerSTRO
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: a12464fa57bf44dc444313525edf65df704ea494ca98cc294c12161ec55f5257
parent: c9f110365a6615ca2c68edbc94f66acfdf9018560829f6d2026b3017590a395e
content hash: 397ddee51ab8d86b898de796a0308749067918b226ea69a0076d9e91400e236e
signed: 2026-04-13T04:47:38.922Z
sources: 20 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf